Related Experiment Video
Updated: Mar 18, 2026
11:30
Multilevel Oblique Lumbar Interbody Fusion in Degenerative Lumbar Disc Disease with Instability
Published on: July 25, 2025
1.5K
A Perspective for Integrating Real-World Evidence Into the Investigational Device Exemption Study Design for Lumbar
David Maislin1, Steven M Kurtz2, Hannah Spece3
1Biomedical Statistical Consulting LLC, Philadelphia, PA, USA.
International Journal of Spine Surgery
|March 16, 2026
Summary
Modern clinical trials for spine devices integrate real-world evidence (RWE) to overcome barriers. This approach accelerates innovation for novel motion-preserving technologies.
Area of Science:
- Spine technology clinical trials
- Medical device innovation
- Regulatory science
Background:
- Investigational device exemption (IDE) studies for spine technologies have evolved from traditional randomized controlled trials (RCTs).
- Modern trials address escalating costs, patient enrollment challenges, and regulatory acceptance of alternative evidence standards.
- The US Food and Drug Administration's increasing acceptance of real-world evidence (RWE) reshapes medical device development.
Purpose of the Study:
- To examine how modern IDE trials integrate RWE to address economic and practical barriers while maintaining scientific validity.
- To analyze the evolution of clinical trial designs for lumbar motion preservation technologies.
- To evaluate the methodological framework of the MOTUS lumbar total joint replacement IDE study.
Main Methods:
- Reviewed evolution of clinical trial designs for lumbar motion preservation technologies (2000-2025).
- Analyzed the MOTUS lumbar total joint replacement IDE study methodology.
- Employed prospective dual-arm enrollment with an investigational arm and an independent RWE control arm, using standardized outcomes and propensity score adjustment.
Main Results:
- Modern IDE trials incorporating RWE offer advantages over traditional RCTs for spine device evaluation.
- The MOTUS IDE study substantially completed enrollment faster than historical RCTs.
- RWE control arms reduced sponsor costs significantly and addressed limitations of traditional RCTs, such as blinding and patient randomization reluctance.
Conclusions:
- Incorporating RWE enables resource-constrained innovators to advance novel spine technologies through the Premarket Approval pathway.
- This approach addresses a critical gap in medical technology innovation, particularly as manufacturers withdraw from lumbar motion preservation development.
- Provides insight into challenges and solutions for clinical trials of novel motion-preserving spine technologies.
